BPH is a prevalent condition among aging males, often associated with bothersome lower urinary tract symptoms and decreased quality of life. Alpha-blockers like Tamsulosin are commonly prescribed to alleviate symptoms by relaxing smooth muscle in the prostate and bladder neck, improving urine flow and reducing lower urinary tract symptoms .

However, while alpha-blockers are effective in managing BPH symptoms, they are associated with adverse effects such as postural hypotension, ejaculatory disorders, and reduced libido, impacting participant compliance and satisfaction. Additionally, they may not address all aspects of BPH, including overactive bladder symptoms, which often coexist with BPH and contribute to the overall burden of the disease.

Given the limitations of existing therapies, there is a need for alternative treatments such as Ural-BPH Capsule, containing a proprietary blend of herbal extracts, presents a promising avenue due to its potential to target multiple aspects of BPH pathophysiology while while maintaining a favorable safety profile by potentially minimizing adverse effects associated with conventional treatments.

By conducting a comparative, randomized clinical trial, this study aims to provide robust evidence regarding the symptomatic relief, urodynamic improvement, and impact on quality of life offered by Ural-BPH Capsule compared to Tamsulosin. Additionally, the trial seeks to assess changes in sexual function, orthostatic tolerance, and safety profiles between the two treatment groups.

The study’s design includes comprehensive assessments encompassing uroflowmetry parameters, urinary symptom scores, PSA(Prostate Specific Antigen) levels, quality of life measures, and safety profiles, thereby offering a holistic evaluation of treatment efficacy and tolerability. Furthermore, the inclusion of hematological and biochemical assessments provides insights into potential systemic effects of the interventions.

Ultimately, the outcomes of this trial will contribute to evidence-based decision-making in the management of BPH, potentially offering a safer and more efficacious alternative to current therapeutic options. By addressing unmet clinical needs and optimizing participant outcomes, this study endeavors to improve the standard of care for individuals suffering from uncomplicated BPH.